San Diego-based CURx Pharmaceuticals has entered into a global license agreement with Gilead Sciences Inc. (Nasdaq: GILD) for the development of Fosfomycin: Tobramycin for Inhalation (FTI) to treat Pseudomonas aeruginosa lung infection in cystic fibrosis patients.
FTI is ready for phase 3 clinical trials, having successfully completed a phase 2 trial in CF patients.
"This is a great acquisition for CURx Pharmaceuticals, which enables us to expand our portfolio and also to provide another inhaled therapeutic to the cystic fibrosis community," said Dinu Sen, CEO and founder of CURx. "Clinical trials in CF patients with Pseudomonas aeruginosa infection have demonstrated FTI's safety and efficacy. Future trials may pave the way for its use against a range of bacterial infections in CF; there is an unmet need for antibiotics with such characteristics."